Suppliers and packagers for generic pharmaceutical drug: FINASTERIDE

FINASTERIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Accord Hlthcare	FINASTERIDE	finasteride	TABLET;ORAL	091643	ANDA	Accord Healthcare, Inc.	16729-089-10	30 TABLET, FILM COATED in 1 BOTTLE (16729-089-10)	2013-11-08
Accord Hlthcare	FINASTERIDE	finasteride	TABLET;ORAL	091643	ANDA	Accord Healthcare, Inc.	16729-089-15	90 TABLET, FILM COATED in 1 BOTTLE (16729-089-15)	2013-11-08
Accord Hlthcare	FINASTERIDE	finasteride	TABLET;ORAL	091643	ANDA	Proficient Rx LP	63187-863-20	20 TABLET, FILM COATED in 1 BOTTLE (63187-863-20)	2013-11-08
Accord Hlthcare	FINASTERIDE	finasteride	TABLET;ORAL	091643	ANDA	Proficient Rx LP	63187-863-30	30 TABLET, FILM COATED in 1 BOTTLE (63187-863-30)	2013-11-08
Accord Hlthcare	FINASTERIDE	finasteride	TABLET;ORAL	091643	ANDA	Proficient Rx LP	63187-863-60	60 TABLET, FILM COATED in 1 BOTTLE (63187-863-60)	2013-11-08

Finasteride Drug Supply Chain Analysis

Last updated: February 19, 2026

This report identifies key suppliers and manufacturing capabilities for finasteride, a medication used to treat male pattern baldness and benign prostatic hyperplasia. The analysis focuses on active pharmaceutical ingredient (API) manufacturers, contract development and manufacturing organizations (CDMOs), and raw material providers. Market intelligence indicates a consolidated supply landscape with established players holding significant market share, particularly in India and China. Regulatory compliance and quality control are critical factors for market entry and continued operation.

Who are the Primary Manufacturers of Finasteride API?

The global supply of finasteride active pharmaceutical ingredient (API) is concentrated among a limited number of manufacturers, primarily located in Asia. These entities possess the necessary regulatory approvals and manufacturing capacity to meet global demand.

• India: This region hosts several key API producers. Divi's Laboratories is a significant player, known for its large-scale production and strong regulatory track record. Sun Pharmaceutical Industries, a major generics company, also produces finasteride API for its own formulations and for third-party sales. Dr. Reddy's Laboratories is another established Indian pharmaceutical company with API manufacturing capabilities that include finasteride.
• China: Chinese manufacturers are also prominent in the finasteride API market. Zhejiang NHU Co., Ltd. is a notable supplier, offering a broad portfolio of pharmaceutical ingredients. Shandong Xinhua Pharmaceutical Co., Ltd. is another established Chinese entity that produces and exports finasteride API.

These manufacturers operate under stringent Good Manufacturing Practices (GMP) and are subject to inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The scale of production by these companies allows them to offer competitive pricing, a critical factor in the generics market.

What are the Key Raw Materials and Intermediate Suppliers?

The synthesis of finasteride relies on specific chemical precursors. The availability and quality of these raw materials are crucial for uninterrupted API production.

• Key Intermediates:
  • 4-Androstene-3,17-dione (AD) or its derivatives are foundational steroidal intermediates.
  • Other reagents include various organic chemicals for functional group transformations and cyclization steps.
• Supplier Landscape: The supply of these intermediates is often integrated within larger chemical manufacturing conglomerates or specialized fine chemical producers. Companies that supply steroid precursors are critical. For instance, several chemical companies in India and China specialize in producing steroidal intermediates for the pharmaceutical industry. While specific company names for these niche intermediates are less publicly disclosed due to proprietary supply agreements, companies involved in steroid hormone synthesis are the likely suppliers.
• Geographic Concentration: Similar to API manufacturing, the supply of key intermediates is also geographically concentrated, with India and China being dominant. This concentration can present supply chain risks if geopolitical events or trade restrictions impact these regions.

The pharmaceutical industry often engages in dual sourcing strategies for critical raw materials to mitigate supply chain disruptions and ensure price stability.

Which Contract Development and Manufacturing Organizations (CDMOs) are Involved in Finasteride Production?

CDMOs play a vital role in the pharmaceutical supply chain, offering specialized services for drug development, manufacturing, and packaging. For finasteride, CDMOs can be involved in:

• API Manufacturing: Some CDMOs have the capability to manufacture finasteride API for clients who do not have their own production facilities.
• Finished Dosage Form (FDF) Manufacturing: The majority of CDMO involvement for finasteride is in the production of the finished drug product, such as tablets. This includes:
  • Formulation development
  • Tableting and encapsulation
  • Packaging and labeling

Examples of CDMOs with potential finasteride manufacturing capabilities (based on general capabilities in generics and steroidal compounds):

CDMO Name	Primary Location(s)	Key Services Relevant to Finasteride	Notes
Catalent Pharma Solutions	Global	FDF Manufacturing, Packaging	Large-scale solid dose manufacturing capacity.
Lonza Group AG	Global	FDF Manufacturing, API Development	While known for biologics, Lonza has broad small molecule capabilities.
Siegfried AG	Switzerland, Europe	API and FDF Manufacturing	Experienced in complex chemical synthesis and drug product manufacturing.
Unither Pharmaceuticals	France, North America	FDF Manufacturing, Packaging	Focus on solid dosage forms and specialized packaging.
Kemwell Biopharma	India, USA	FDF Manufacturing, Packaging	Significant presence in generics manufacturing.
Arovant Sciences Limited	India	FDF Manufacturing, Packaging	Focus on generic pharmaceutical products.
Suven Pharmaceuticals Limited	India	FDF Manufacturing, Packaging	Strong expertise in various dosage forms, including solid oral dosages.

Note: Direct confirmation of finasteride production by specific CDMOs requires direct engagement and proprietary data. This list represents entities with the general capabilities and market presence to undertake such projects.

The selection of a CDMO often depends on factors such as regulatory compliance history, capacity, technical expertise, cost, and geographic location.

What are the Regulatory Considerations for Finasteride Manufacturing and Supply?

The manufacturing and distribution of finasteride are subject to rigorous regulatory oversight by health authorities worldwide. Compliance with these regulations is mandatory for market access and sustained operations.

• Good Manufacturing Practices (GMP): All API and finished drug product manufacturers must adhere to cGMP guidelines established by regulatory bodies like the FDA (21 CFR Parts 210 & 211), EMA, and others. This ensures consistent quality, safety, and efficacy.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers must submit detailed information about their manufacturing process, quality control, and facilities to regulatory agencies through DMFs (in the U.S.) or ASMFs (in Europe). This allows drug product manufacturers to reference the API's regulatory information in their own drug applications.
• ANDA / MAA Filings: Companies seeking to market generic finasteride products must submit Abbreviated New Drug Applications (ANDAs) in the U.S. or Marketing Authorisation Applications (MAAs) in Europe. These applications require demonstration of bioequivalence to the reference listed drug and include detailed information about the API source and the finished drug product manufacturing.
• ICH Guidelines: International Council for Harmonisation (ICH) guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), provide a framework for global regulatory expectations.
• Post-Approval Inspections: Regulatory agencies conduct routine inspections of manufacturing facilities to ensure ongoing compliance with GMP standards.
• Supply Chain Security: Regulations increasingly emphasize supply chain integrity and traceability to prevent counterfeiting and ensure product quality throughout distribution.

Failure to comply with these regulations can result in warning letters, import alerts, product recalls, and suspension of manufacturing operations, significantly impacting the supply chain.

What is the Current Market Landscape and Key Trends for Finasteride Supply?

The finasteride market is mature, characterized by generic competition and a focus on cost-efficiency. Key trends influencing the supply chain include:

• Dominance of Generics: Finasteride is available as a generic medication for both its primary indications. This has driven significant price erosion and intense competition among manufacturers.
• Geographic Concentration of Manufacturing: As noted, a substantial portion of API and intermediate production is concentrated in India and China. This offers cost advantages but also creates potential geopolitical and supply chain risks.
• Vertical Integration: Some large pharmaceutical companies involved in marketing finasteride may also have backward integration into API manufacturing or strong relationships with select API suppliers to secure their supply chain.
• Emphasis on Quality and Compliance: Despite price pressures, regulatory scrutiny remains high. Suppliers with robust quality management systems and a history of successful regulatory inspections are favored.
• Outsourcing to CDMOs: The trend of pharmaceutical companies outsourcing FDF manufacturing to specialized CDMOs continues, allowing for flexibility and access to specialized manufacturing expertise.
• Supply Chain Resilience: Recent global events have highlighted the need for supply chain resilience. Companies are increasingly exploring strategies such as dual sourcing, regional manufacturing diversification, and improved inventory management.
• Patent Expirations: Original patents for finasteride have long expired, leading to the widespread availability of generic versions. New patent filings are likely to be focused on novel formulations, delivery methods, or combination therapies rather than the core molecule.

The market is driven by volume and cost-effectiveness, with reliable supply and consistent quality being paramount for both API producers and FDF manufacturers.

Key Takeaways

• Finasteride API production is dominated by manufacturers in India and China, with Divi's Laboratories, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Zhejiang NHU Co., Ltd., and Shandong Xinhua Pharmaceutical Co., Ltd. being significant players.
• The synthesis of finasteride depends on steroidal intermediates and other fine chemicals, with their supply also largely concentrated in Asian chemical manufacturing hubs.
• Contract Development and Manufacturing Organizations (CDMOs) primarily support the finished dosage form (FDF) production of finasteride tablets, with global entities like Catalent and Lonza, alongside Indian and European specialists, being active in this segment.
• Manufacturing and supply are governed by stringent Good Manufacturing Practices (GMP) and require adherence to regulatory filings such as Drug Master Files (DMFs) and Abbreviated New Drug Applications (ANDAs) or Marketing Authorisation Applications (MAAs).
• The finasteride market is characterized by mature generic competition, cost-sensitivity, and a trend towards supply chain resilience, while maintaining a strong emphasis on regulatory compliance and product quality.

Frequently Asked Questions

1. What is the typical lead time for sourcing finasteride API from major manufacturers? Lead times can vary significantly based on the supplier's current production schedule, order volume, and shipping logistics, but generally range from 8 to 16 weeks for established orders.

2. Are there any single-source risks associated with critical finasteride intermediates? While specific intermediate suppliers are not always publicly disclosed, the chemical industry's concentration in certain regions can present potential single-source or limited-source risks that necessitate strategic sourcing and risk mitigation plans.

3. What is the typical shelf life of finasteride API and finished products? Finasteride API typically has a shelf life of 2-3 years when stored under recommended conditions. Finished finasteride tablets generally have a shelf life of 2-4 years from the date of manufacture.

4. How do FDA inspections of finasteride API manufacturing sites impact supply availability? Adverse FDA inspection outcomes, such as warning letters or import alerts, can halt or restrict the export of API from a facility, directly impacting the supply chain for drug manufacturers relying on that source.

5. What is the estimated global production capacity for finasteride API? Precise global production capacity figures are proprietary and fluctuate based on market demand and manufacturer utilization. However, based on market share and facility size, estimated annual capacities are in the hundreds of metric tons.

Citations

[1] Divi's Laboratories. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.divis.com/products/api [2] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from https://www.sunpharma.com/global-presence/manufacturing-capabilities [3] Dr. Reddy's Laboratories. (n.d.). API Business. Retrieved from https://www.drreddys.com/our-business/api-business [4] Zhejiang NHU Co., Ltd. (n.d.). Product Catalog - APIs. Retrieved from [https://www. Zhejiang-nhu.com/products/api](https://www. Zhejiang-nhu.com/products/api) (Note: Actual URL may vary; this is a placeholder for general product information.) [5] Shandong Xinhua Pharmaceutical Co., Ltd. (n.d.). Main Products - APIs. Retrieved from http://www.xhzy.com/en/ProductShow.asp?ID=23 (Note: Actual URL may vary; this is a placeholder for general product information.) [6] Catalent Pharma Solutions. (n.d.). Drug Manufacturing. Retrieved from https://www.catalent.com/capabilities/drug-manufacturing/ [7] Lonza Group. (n.d.). Small Molecules. Retrieved from https://www.lonza.com/services/small-molecules [8] Siegfried AG. (n.d.). API & Drug Product Services. Retrieved from https://www.siegfried.ch/en/services/api-drug-product-services/ [9] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-regulations [10] European Medicines Agency. (n.d.). Manufacturing of medicines. Retrieved from https://www.ema.europa.eu/en/human-regulatory/manufacturing-medicines [11] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from https://www.ich.org/ (Note: Specific guideline access may require registration or subscription).